Páramo Fernández José A
Servicio de Hematología y Hemoterapia, CUN, Laboratorio de Aterotrombosis CIMA, Universidad de Navarra, CIBERCV, Pamplona, España.
Clin Investig Arterioscler. 2018 May-Jun;30(3):133-136. doi: 10.1016/j.arteri.2018.03.001. Epub 2018 Apr 23.
Recent research has revealed that clonal hematopoyesis of indeterminate potential (CHIP) characterized by the acquisition of somatic mutations in hematopoietic stem cells, is not only a common age-related disorder and a premalignant condition, but it is also associated with the development of atherosclerotic vascular diseases. Mutations in DNMT3A, TET2 and ASXL1 were each individually associated with coronary heart disease, stroke and coronary calcification. Therefore, CHIP emerges as a new risk factor for atherosclerotic vascular pathologies and its detection may be relevant as a new therapeutic target in order to modify the natural course of the disease.
最近的研究表明,以造血干细胞中获得体细胞突变为特征的不确定潜能克隆性造血(CHIP),不仅是一种常见的与年龄相关的疾病和癌前状态,还与动脉粥样硬化性血管疾病的发生有关。DNMT3A、TET2和ASXL1的突变各自都与冠心病、中风和冠状动脉钙化相关。因此,CHIP成为动脉粥样硬化性血管病变的一个新的危险因素,对其进行检测可能作为一个新的治疗靶点具有重要意义,以便改变疾病的自然进程。